ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2155 entries already.
The AI Health Innovation Cluster is bringing together leading scientists at the interface
of artificial intelligence (AI), healthcare, and data science. The goal is to combine and further develop the outstanding research networks and infrastructures in modern health data sciences that have emerged in the Rhine-Neckar region in Germany in recent years.
Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
SARS-COV-2 exposed our vulnerability and strategic weakness at European level, in terms of biotechnological manufacturing capacity.
With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Cipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.
Scientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.
One of the most distinguishing hallmarks of tumours is their ability to avoid immune recognition. New immunotherapies have focused on breaking down those barriers, leading to treatment breakthroughs for blood cancers. While these therapies have shown great promise for some indications, we still lack effective therapies for many others. A novel route to address this is to the restore innate immunity’s ability to fight cancer.
The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.
"Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – in other words, to adapt it to the natural cycles of our planet.